Shares of the company are trading at $1.37 a bit higher than $1.28, the 50 day moving average and much lower than the 200 day moving average of $3.30. The 50 day moving average was up $0.09 or +6.86% and the 200 day average moved down $-1.93. (NASDAQ:CUR) shares saw heavy trading volume with 600K shares changing hands on Tuesday. Trading volume was up 896.19% over the stocks average daily volume.
Traders are feeling more bullish lately considering the decrease in short interest. The company realized a fall in short interest between September 15, 2017 and September 29, 2017 of -46.06%. Short interest fell 409,363 over that timeframe. With short interest at 479,425 and short average daily volume at 1,367,130, days to cover is 0.0 and the percentage of shorted shares is 0.04% as of September 29.
These funds have shifted positions in (CUR). As of the end of the quarter Citadel Advisors LLC had acquired 45,187 shares growing its position 400.3%. The value of the investment in Neuralstem, Inc. increased from $3,000 to $42,000 increasing 1,300.0% for the reporting period.
Neuralstem, Inc. (Neuralstem), launched on February 28, 2001, is a clinical-stage biopharmaceutical company. The Company is involved in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Business’s technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions..